Carbonic anhydrase (CA) arose significant interest as a potential new target for Chagas disease since its discovery in Trypanosoma cruzi in 2013. Benznidazole and Nifurtimox have been used for Chagas disease treatment for 60 years despite all efforts done for obtaining more efficient treatments, acting in the acute and chronic phases of illness, with fewer side effects and resistance induction.
Discovery of novel drugs for Chagas disease: is carbonic anhydrase a target for antiprotozoal drugs? / Beatriz Vermelho, Alane; Rodrigues, Giseli Capaci; Nocentini, Alessio; Mansoldo, Felipe R P; Supuran, Claudiu T. - In: EXPERT OPINION ON DRUG DISCOVERY. - ISSN 1746-045X. - ELETTRONICO. - 17:(2022), pp. 1147-1158. [10.1080/17460441.2022.2117295]
Discovery of novel drugs for Chagas disease: is carbonic anhydrase a target for antiprotozoal drugs?
Nocentini, Alessio;Supuran, Claudiu T
2022
Abstract
Carbonic anhydrase (CA) arose significant interest as a potential new target for Chagas disease since its discovery in Trypanosoma cruzi in 2013. Benznidazole and Nifurtimox have been used for Chagas disease treatment for 60 years despite all efforts done for obtaining more efficient treatments, acting in the acute and chronic phases of illness, with fewer side effects and resistance induction.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
